A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Inclusion Criteria:

• All participants must have a histologically or cytologically confirmed, advanced,unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and havereceived, be refractory to, ineligible for, intolerant of, or refused existingtherapy(ies) known to provide clinical benefit for the condition of the participant.

• Participant must be ≥ 18 years or the legal age of consent in the jurisdiction inwhich the study is taking place, inclusive, at the time of signing the ICF.

• Participants in Part 1A may have NSCLC, SCCHN, MSS-CRC, gastric/GEJ adenocarcinoma,urothelial carcinoma, PDAC, melanoma or breast cancer (TNBC and ER+HER2-).

• Participants in Part 1B1 and 2B1 must have NSCLC and, if known, should havedocumented status for EGFR, KRAS, ALK, ROS1, RET, NTRK, MET exon 14 skippingmutations, and BRAF V600E.Participants must have received platinum-basedchemotherapy and anti-PD-(L)1 therapy, if eligible and available.

• Participants in Parts 1B2, 2B2, and 1C must have cutaneous, acral, mucosal, orunknown primary melanoma. Participants with uveal/ocular melanoma are excluded.Participants must be melanoma 2L+.

• Participants in Part 1B3 must have advanced or metastatic MSS-CRC.

• Participants in Part 2A may have advanced solid tumors (advanced, unresectable, ormetastatic NSCLC, advanced, unresectable, hormone resistant ER+HER2-breast cancer orpancreatic adenocarcinoma [PDAC]) based on emerging data.

• Participants in Part 2B3 must have advanced or metastatic MSS-CRC.

• For all participants in Part 1C cohort, a tumor sample from a ("fresh") biopsy [corebiopsy (at least 4 passages recommended), punch biopsy, excisional biopsy orsurgical specimen] must be obtained (obtained within 1 month of the start of theScreening, if there are tumor sites that can be biopsied with acceptable clinicalrisk).

Exclusion Criteria:

• History of life threatening immune mediated toxicity related to prior T-cell agonistor checkpoint inhibitor therapy, except those that are unlikely to re-occur withstandard countermeasures.

• Any significant acute or chronic medical illness which would interfere with studyintervention or follow-up in the opinion of the investigator.

• Other protocol-defined Inclusion/Exclusion criteria apply.